US-based Lantheus Holdings becomes largest shareholder in Radiopharm Theranostics after US$5 million private placement.
Lipoprotein(a) doesn’t influence calcification or outcomes in TAVR, shifting focus to other AS progression factors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback